Background: Diabetic macular oedema is a frequent cause of visual loss in pati ents with diabetic retinopathy. The purpose of this study was to assess the effi cacy of intravitreal triamcinolone acetonide in reducing ...Background: Diabetic macular oedema is a frequent cause of visual loss in pati ents with diabetic retinopathy. The purpose of this study was to assess the effi cacy of intravitreal triamcinolone acetonide in reducing diabetic macular oedema and improving visual acuity. Methods: In this prospective study 12 eyes of 12 p atients with diabetic macular oedema unresponsive to prior laser treatment recei ved an intravitreal injection of 4 mg triamcinolone acetonide. Examinations were performed 1 day preoperatively and at 1 week and 1, 3, 6, and 9 months after su rgery and included slit-lamp examination, measurement of IOP, assessment of dis tance as well as reading visual acuity and assessment of macular thickness using optical coherence tomography (OCT). Results: Mean age of the patients (mean±SD ) was 66.6±8.6 years. Mean best-corrected visual acuity (BCVA) for distance (L ogMAR using ETDRS charts) improved from 1.0±0.4 preoperatively to 0.9±0.4 (p=0 .01) 1 week and to 0.9±0.4 (p=0.02) 1month postoperatively. Mean BCVA for readi ng vision (LogRAD using Radner Reading Charts) improved from 1.1±0.4 preoperati vely to 0.9±0.4 (p=0.002) 1 month postoperatively. Mean macular thickness decre ased from 450±190 (μm) preoperatively to 305±153 (p=0.02) 1 month postoperati vely. No significant improvement in VA and no significant reduction of macular thickness could be observed 3, 6 , and 9 months postoperatively. Mean intraocular pressure significantly increase d from 14.7±2.7mmHg preoperatively to 16.9±3.0 mmHg at 1 month (p=0.02). Concl usion: A single intravitreal injection of triamcinolone acetonide led to a signi ficant improvement in mean VA in patients with diabetic macular oedema. However, the significant effect was not permanent and persisted for only 1 month.展开更多
文摘Background: Diabetic macular oedema is a frequent cause of visual loss in pati ents with diabetic retinopathy. The purpose of this study was to assess the effi cacy of intravitreal triamcinolone acetonide in reducing diabetic macular oedema and improving visual acuity. Methods: In this prospective study 12 eyes of 12 p atients with diabetic macular oedema unresponsive to prior laser treatment recei ved an intravitreal injection of 4 mg triamcinolone acetonide. Examinations were performed 1 day preoperatively and at 1 week and 1, 3, 6, and 9 months after su rgery and included slit-lamp examination, measurement of IOP, assessment of dis tance as well as reading visual acuity and assessment of macular thickness using optical coherence tomography (OCT). Results: Mean age of the patients (mean±SD ) was 66.6±8.6 years. Mean best-corrected visual acuity (BCVA) for distance (L ogMAR using ETDRS charts) improved from 1.0±0.4 preoperatively to 0.9±0.4 (p=0 .01) 1 week and to 0.9±0.4 (p=0.02) 1month postoperatively. Mean BCVA for readi ng vision (LogRAD using Radner Reading Charts) improved from 1.1±0.4 preoperati vely to 0.9±0.4 (p=0.002) 1 month postoperatively. Mean macular thickness decre ased from 450±190 (μm) preoperatively to 305±153 (p=0.02) 1 month postoperati vely. No significant improvement in VA and no significant reduction of macular thickness could be observed 3, 6 , and 9 months postoperatively. Mean intraocular pressure significantly increase d from 14.7±2.7mmHg preoperatively to 16.9±3.0 mmHg at 1 month (p=0.02). Concl usion: A single intravitreal injection of triamcinolone acetonide led to a signi ficant improvement in mean VA in patients with diabetic macular oedema. However, the significant effect was not permanent and persisted for only 1 month.
